Candel Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Candel Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Candel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value Indexes During 2025 Annual Reconstitution
The development tests whether Candel Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Candel Therapeutics, Inc. Announces Appointment of Maha Radhakrishnan, M.D. to Board of Directors
The story matters when it changes Candel Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest CADL filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Candel Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →